Protalix BioTherapeutics financials
$2.690.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M | $34.2M | $21.1M | $9.2M |
| Gross profit | $25.8M | $29.1M | $42.5M | $28.0M | $22.0M | $52.0M | $43.8M | $24.9M | $5.8M | $801.0K |
| Gross margin | 48.8% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% | 80.1% | 72.8% | 27.7% | 8.7% |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M | -$20.5M | $2.7M | -$10.7M | -$19.3M | -$34.5M | -$33.2M |
| Net income | -$6.6M | $2.9M | $8.3M | -$14.9M | -$27.6M | -$6.5M | -$18.3M | -$26.5M | -$83.4M | -$29.4M |
| Net margin | −12.5% | 5.5% | 12.7% | −31.3% | −71.9% | −10.4% | −33.4% | −77.3% | −395.9% | −319.2% |
| Diluted EPS | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 | $-0.22 | $-1.23 | $-1.80 | $-6.37 | $-2.90 |
| EBITDA | -$4.0M | $5.2M | $11.7M | -$11.9M | -$19.3M | $4.0M | -$9.1M | -$17.6M | -$32.6M | -$31.2M |
| Operating cash flow | -$12.0M | $8.7M | -$1.3M | -$25.0M | -$10.3M | -$26.1M | -$19.4M | -$7.7M | -$10.0M | -$32.1M |
| Free cash flow | -$13.6M | $7.4M | -$2.5M | -$25.6M | -$11.7M | -$26.8M | -$20.0M | -$8.4M | -$11.0M | -$32.9M |
| Diluted shares | 78.5M | 81.1M | 82.4M | 48.5M | 44.1M | 29.1M | 14.8M | 14.7M | 13.1M | 10.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M | $18.3M |
| Short-term investments | $15.6M | $15.1M | $20.9M | $5.1M | $0.00 | $20.3M |
| Total debt | $0.00 | $0.00 | $20.3M | $28.2M | $27.9M | $58.5M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M | $67.9M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M | $95.0M |
| Shareholders' equity | $48.2M | $43.2M | $33.6M | -$10.6M | -$6.0M | -$27.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology